Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
BioElectronics Shareholders BIEL
Group post by Gary Jacobs · 19m ·
I'm starting to see SEC documents of other biotechnology companies increasing attention and research into PEMF. There will be competition from big pharma.
BIEL is working to become the benchmark standard of care as a publicly-traded entity it must also be an appealing investment. I trust that management is working toward both of those objectives.
BioElectronics Shareholders BIEL
Group post by Kelly Whelan · 46m ·
Keith is in his office. He has not left the Company.
I would say adding fertilizer to the pile
LMAO FALSE INFO ADDING TO The Fertilizer PILE
Thanks, I agree The posts related to Biel are the BIGGEST BS
Go Biel
FALSE INFO IN POST RELATED TO BIEL JUST PURE BS
The post related to Biel is the most uninteresting junk
Biggest Misinformation ever posted related to pink sheet trading and Biel, Come On Man, Really!!!!!!
FALSE INFO RELATED TO BIEL LMAO
Go BIEL
WOW What A Worthless Post Related To Biel
Sales-Increasing-for-last-two-Quarter-Just-Facts-NO-BS
Did you notice the BUYING of Biel?
Sales Increasing for last two Quarter Just Facts
Sorry Proof is on you, your post stating no buyout thanks will be waiting
Baloney LMAO Scams do not last for 15 years GEEEZZZZ
BS need proof about no buyout related to ELTP in the post
Congrats TooHot on the new Biel mod., be sure to read the mod guidelines and follow them.
First-quarter sales were $605,675 which is 18% higher than Q4 2020 sales, and an impressive 73% of total 2020 revenue; these percentage increases not only document the Company’s strong growth but also serve as objective evidence of effectiveness for the Company’s strategic repositioning as an OEM manufacturer. The Q1 2021 sales figure is robust, as there is over $306,000 of deferred sales incoming from signed contracts, for products that have yet to be shipped.
Looking ahead, the Company is now working with their three major channel partners, i.e., KT Health and Scott Specialties in the OTC space, and Medi-Launch in the prescription medical market, to solidify new orders after strong initial product launches that took place in Q1 2021. Kelly Whelan, President & CEO, expressed enthusiasm, “Initial OTC feedback has been very positive, as witnessed by strong consumer reviews (averaging over 4.5 out of 5 on Amazon.com and their company websites) for both the KT Recovery+ Wave™ and DonJoy® EME products. The launch into the medical channel was slowed by the pandemic but has recently accelerated as hospitals are resuming non-emergency surgical procedures.”
The Company is also pushing forward on the international sales front. In addition to re-acquiring their CE mark (which allows the Company to sell in most international countries) in late 2020, it also obtained MDSAP certification in Q1 2021, which now allows for product distribution in Canada, Australia, and New Zealand. Ms. Whelan also said, “We are now exploring expanding our OTC sales into more countries in the EU using the same strategy of identifying firms with strong retail experience selling their branded products into the retail market. We hope to be able to announce the results of these conversations in the near future. In addition, through Medi-Launch, we have signed four new international distributorships contracts for our RecoveryRx line.”
Mr. Richard Staelin, Chairman of the Board, commented, “We believe it is important to keep investing in one of our core capabilities, i.e., designing and manufacturing Pulsed Short Wave Therapy medical devices. With this in mind, we are in active talks to conduct new clinical trials both with our RecoveryRx product and extensions of our OTC devices. We are also working with our contract manufacturer to strengthen our manufacturing capabilities to accommodate for increased production, amid international volatility in raw material costs.”
BIEL is heating up again in recent trading and looking to break out northbound again. Microcapdaily has been reporting on BIEL for years and covered them in triple digits back in November shortly after the Company received CE (Conformité Européenne) Mark for its ActiPatch® and RecoveryRx®. These wearable devices can now be sold over the counter in 33 European Union (EU) countries, and many other non-EU countries like Australia that recognize the CE mark. This comes shortly after the Company acquired three 510(k) clearances from the U.S. Food & Drug Administration (FDA). Currently under heavy accumulation BIEL is looking to blaze a path along the likes of Enzolytics or Tesoro and break out into a whole new dimension – Tesoro went to multi dollars – a break over $0.008 and its blue skies ahead. BIEL has been busy since executing the OEM agreement with KT Health in December; the Company is now working with their three major channel partners, i.e., KT Health and Scott Specialties in the OTC space, and Medi-Launch in the prescription medical market, to solidify new orders after strong initial product launches that took place in Q1 2021. The Company is also pushing forward on the international sales front. In addition to re-acquiring their CE mark (which allows the Company to sell in most international countries) in late 2020, it also obtained MDSAP certification in Q1 2021, which now allows for product distribution in Canada, Australia, and New Zealand. Sales have risen briskly; On April 21 BIEL reported First quarter Q1 sales were $605,675 which is 18% higher than Q4 2020 sales, and an impressive 73% of total 2020 revenue; these percentage increases not only document the Company’s strong growth, but also serve as objective evidence of effectiveness for the Company’s strategic repositioning as an OEM manufacturer. The Q1 2021 sales figure is robust, as there is over $306,000 of deferred sales incoming from signed contracts, for products that have yet to be shipped. BIEL has a mammoth shareholder base; ready liquidity and a long history of breakout moves. We will be updating on BIEL when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with BIEL.
On April 19 BIEL reported Q1 2021 revenue figures, the progress on three different product launches into the OTC and medical markets, ongoing efforts to expand international distribution, and finally, new initiatives into strengthening R&D/manufacturing capabilities.
Disclosure: we hold no position in BIEL either long or short and we have not been compensated for this article.
4/21/2021 9:16:34 AM
It's in the PR First-quarter sales were $605,675 which is 18% higher than Q4 2020 sales, and an impressive 73% of total 2020 revenue; these percentage increases not only document the Company’s strong growth but also serve as objective evidence of effectiveness for the Company’s strategic repositioning as an OEM manufacturer. The Q1 2021 sales figure is robust, as there is over $306,000 of deferred sales incoming from signed contracts, for products that have yet to be shipped.
First-quarter sales were $605,675 which is 18% higher than Q4 2020 sales, and an impressive 73% of total 2020 revenue; these percentage increases not only document the Company’s strong growth but also serve as objective evidence of effectiveness for the Company’s strategic repositioning as an OEM manufacturer. The Q1 2021 sales figure is robust, as there is over $306,000 of deferred sales incoming from signed contracts, for products that have yet to be shipped.
We have had some good runs and pull back and looks like it fixing to run hard, good things happening with Biel. Hope you have been well.
BioElectronics Corporation Reports Double Digit Quarterly Sales Growth, KT Health and DJO Launches Outpacing Forecasts
BIEL
+19.23%
FREDERICK, MD, April 19, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioElectronics Corporation (https://www.bielcorp.com/ OTC PINK: BIEL) is pleased to report Q1 2021 revenue figures, the progress on three different product launches into the OTC and medical markets, ongoing efforts to expand international distribution, and finally, new initiatives into strengthening R&D/manufacturing capabilities.
First-quarter sales were $605,675 which is 18% higher than Q4 2020 sales, and an impressive 73% of total 2020 revenue; these percentage increases not only document the Company’s strong growth but also serve as objective evidence of effectiveness for the Company’s strategic repositioning as an OEM manufacturer. The Q1 2021 sales figure is robust, as there is over $306,000 of deferred sales incoming from signed contracts, for products that have yet to be shipped.
Looking ahead, the Company is now working with their three major channel partners, i.e., KT Health and Scott Specialties in the OTC space, and Medi-Launch in the prescription medical market, to solidify new orders after strong initial product launches that took place in Q1 2021. Kelly Whelan, President & CEO, expressed enthusiasm, “Initial OTC feedback has been very positive, as witnessed by strong consumer reviews (averaging over 4.5 out of 5 on Amazon.com and their company websites) for both the KT Recovery+ Wave™ and DonJoy® EME products. The launch into the medical channel was slowed by the pandemic but has recently accelerated as hospitals are resuming non-emergency surgical procedures.”
The Company is also pushing forward on the international sales front. In addition to re-acquiring their CE mark (which allows the Company to sell in most international countries) in late 2020, it also obtained MDSAP certification in Q1 2021, which now allows for product distribution in Canada, Australia, and New Zealand. Ms. Whelan also said, “We are now exploring expanding our OTC sales into more countries in the EU using the same strategy of identifying firms with strong retail experience selling their branded products into the retail market. We hope to be able to announce the results of these conversations in the near future. In addition, through Medi-Launch, we have signed four new international distributorships contracts for our RecoveryRx line.”
Mr. Richard Staelin, Chairman of the Board, commented, “We believe it is important to keep investing in one of our core capabilities, i.e., designing and manufacturing Pulsed Short Wave Therapy medical devices. With this in mind, we are in active talks to conduct new clinical trials both with our RecoveryRx product and extensions of our OTC devices. We are also working with our contract manufacturer to strengthen our manufacturing capabilities to accommodate for increased production, amid international volatility in raw material costs.”
Disclosure
Certain information set forth in this email contains “forward-looking information”, including “future-oriented financial information” and “financial outlook”, under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, the information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of the Company; (ii) completion of, and the use of proceeds from, the sale of the shares being offered hereunder; (iii) the expected development of the Company’s business, projects, and joint ventures; (iv) execution of the Company’s vision and growth strategy, including with respect to future M&A activity and global growth; (v) sources and availability of third-party financing for the Company’s projects; (vi) completion of the Company’s projects that are currently underway, in development or otherwise under consideration; (vi) renewal of the Company’s current customer, supplier and other material agreements; and (vii) future liquidity, working capital, and capital requirements. Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment.
These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.
Although forward-looking statements contained in this email are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.
Contact: Paul Knopick
pknopick@eandecommunications.com
940.262.3584
Mon, Apr 19 at 7:15 AM
Release #:812-202097-rl-1141231:
4/19/2021 8:15:37 AM
So true same old crap post related to Biel
Sorry since 2006 over 1,000+ times I have heard it LOL
1st Q of 2021 is complete Go Biel
Go Biel
KT Recovery Wave is a breakthrough in drug-free pain relief. We have taken clinically proven electromagnetic therapy from the clinician's office and brought it to you as an easy to use and portable FDA cleared device. What was once an expensive, bulky clinical & sports therapy treatment is now lightweight, dis-creet, and wearable - to go wherever you go Clinically proven and FDA cleared device for pain relief
Effective drug-free at-home use
Safe undetectable electromagnetic pulses
Use the provided strips to adhere the device or KT Tape kinesiology tape to provide added pain relief and support.
Flexible loop is easy to place for active use
Can be worn under clothing
Water resistant
More...
BUY NOW
KT Recovery+ Wave product
https://www.kttape.com/pages/kt-recovery-wave
LMAO that is BS
1. 100 - I need Shares. Sell Your Share LMAO
2. 200 - I need Shares badly but do not take the stock down.
3. 300 - Take (or I am taking) the stock down at least 30% so I can load shares.
4. 400 - Keep trading it sideways.
5. 500 - Gap the stock. Gap can be up or down, depending on direction of 500 signal.
6. 505 - I am short on shares
7. 600 - Apply resistance at the ASK to keep the price from increasing.
8. 700 - Move the price up.
9. 777 - Also recognized as a signal to move the price up.
10. 800 - Prepare for an increase in trading volume.
11. 900 - Allow the stock to float and trade freely.
12. 911 - Pending News/Press Release On The Way
13. 1000 - Don't let it run
14. 2100 - Let it run
http://www.pennystockdream.com/Market-Maker-Signals
LMAO Actipatch is the chronic pain relief NOT KT Tape GEEEZZZZ
Let The Good Times Roll On Biel Wonder What News Is Coming
Extended hours $0.0055+0.0006 (+13.05%) E*Trade
Waste of time reading the BS post pump and dump related to BIEl has not changed anything and not going to change anything
Wow-Really-I-guess-that-is-why-1.7-BILLION Shares Have Traded In 11 DAYS LMAO
Date Close Change Change (%) Open High Low Volume
Feb 08 2021 0.004 0.0004 11.11% 0.0036 0.004 0.0036 187,013,985
Feb 05 2021 0.0036 0.0001 2.86% 0.003 0.0037 0.003 64,020,043
Feb 04 2021 0.0035 -0.0002 -5.41% 0.0038 0.0039 0.0033 97,265,355
Feb 03 2021 0.0037 -0.0002 -5.13% 0.004 0.004 0.0034 77,889,821
Feb 02 2021 0.0039 -0.0001 -2.5% 0.004 0.004 0.0037 69,683,937
Feb 01 2021 0.004 0.00075 23.08% 0.0033 0.004 0.00319 147,665,515
Jan 29 2021 0.00325 0.00015 4.84% 0.0032 0.0033 0.003 57,626,159
Jan 28 2021 0.0031 0.00 0.0% 0.0031 0.0033 0.0028 87,495,963
Jan 27 2021 0.0031 -0.00085 -21.52% 0.004 0.0041 0.0028 298,292,381
Jan 26 2021 0.00395 0.00158 66.46% 0.003 0.004 0.00245 426,282,131
Jan 25 2021 0.002373 0.00027 13.0% 0.0022 0.0025 0.0021 122,852,882
All the false info related to BIEL is not going to change anything LMAO
LMAO WHO CARES ALREADY BEEN CLEARED BY FDA
Long-story-short-BIEL-is-The-BEST-Better-Buy-and-Not-Chase
LMAO Thanks for all the Pig Crap posts related to Biel all the bullshit posts related to Biel will not change the direction of BIEL